Trial Profile
An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Luliconazole (Primary)
- Indications Tinea cruris; Tinea pedis
- Focus Pharmacokinetics
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 12 May 2016 New trial record